Guggenheim Capital’s Protagonist Therapeutics PTGX Stock Holding History

Guggenheim Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.67M	Buy	21,800 +6,520	+43%	+$681K	0.02%	639
2026 Q1	$1.61M	Sell	15,280 -15,816	-51%	-$1.4M	0.01%	781
2025 Q4	$2.72M	Buy	31,096 +12,513	+67%	+$1.02M	0.02%	584
2025 Q3	$1.23M	Sell	18,583 -625	-3%	-$35.5K	0.01%	849
2025 Q2	$1.06M	Buy	19,208 +303	+2%	+$14.5K	0.01%	869
2025 Q1	$914K	Sell	18,905 -173	-0.9%	-$7.25K	0.01%	914
2024 Q4	$736K	Buy	19,078 +11,180	+142%	+$487K	0.01%	1070
2024 Q3	$355K	Buy	+7,898	New	+$319K	﹤0.01%	1541

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Guggenheim Capital's PTGX Position: Q2 2026 in Review

Guggenheim Capital increased its Protagonist Therapeutics (PTGX) stake by 43% in Q2 2026, buying an estimated $681K and bringing the position to 21,800 shares worth $2.67M. The position accounts for 0.02% of the portfolio, ranked #639.

Guggenheim Capital first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.72M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Guggenheim Capital held 21,800 shares of Protagonist Therapeutics worth $2.67M as of Q2 2026.
Guggenheim Capital bought 6,520 Protagonist Therapeutics shares in Q2 2026, an estimated $681K.
Protagonist Therapeutics made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #639 holding.
Guggenheim Capital first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
Guggenheim Capital's Protagonist Therapeutics position peaked at $2.72M in Q4 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.